<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01799863</url>
  </required_header>
  <id_info>
    <org_study_id>FAV011_12</org_study_id>
    <nct_id>NCT01799863</nct_id>
  </id_info>
  <brief_title>Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis</brief_title>
  <official_title>Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Treatment of Acute Viral Conjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundação Altino Ventura</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundação Altino Ventura</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the evolution of the symptoms of acute viral
      conjunctivitis using preservative free ketorolac trometamol 0.45% associated with
      carboxymethylcellulose compared with isolated use of preservative-free artificial tears.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the evolution of the symptoms of acute viral
      conjunctivitis using preservative free ketorolac trometamol 0.45% associated with
      carboxymethylcellulose compared with isolated use of preservative-free artificial tears. A
      randomized double-masked study will include 60 patients divided into two groups: Group 1:
      using a formulation of ketorolac tromethamine 0.45% associated with carboxymethylcellulose
      (Acular CMC®, Allergan, Irvine, USA) and Group 0: using artificial tears (Optive UD®,
      Allergan, Irvine, USA), both drugs without preservatives.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in ocular symptoms from baseline to treatment day 7</measure>
    <time_frame>7 days</time_frame>
    <description>General ocular discomfort, itching, foreign body sensation, tearing, eye redness and eyelid edema. Symptoms will be graded as 0 (absence), I (mild), II (moderate) and III (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ocular signs from baseline to treatment day 7</measure>
    <time_frame>7 days</time_frame>
    <description>The clinical examination will consist of slit-lamp examination of the anterior segment. Four signs will be assessed: conjunctival hyperemia, chemosis, secretion and follicles in lower tarsal conjunctiva. The signs will be classified as 0 (absence), I (mild), II (moderate), III (severe)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Conjunctivitis, Viral</condition>
  <arm_group>
    <arm_group_label>Ketorolac trometamol 0.45%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketorolac trometamol 0.45% associated with carboxymethylcellulose eye drops (Acular CMC®, Allergan, Irvine, USA) qid for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Artificial tears</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Preservative free artificial tears (Optive UD®, Allergan, Irvine, USA) qid for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac trometamol 0.45% with carboxymethylcellulose</intervention_name>
    <arm_group_label>Ketorolac trometamol 0.45%</arm_group_label>
    <other_name>Acular CMC®, Allergan, Irvine, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preservative free artificial tear</intervention_name>
    <arm_group_label>Artificial tears</arm_group_label>
    <other_name>Optive UD®, Allergan, Irvine, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute conjunctivitis (unilateral or bilateral) for less than two weeks,

          -  Signs and symptoms consistent with viral conjunctivitis and at least one of the
             following: preauricular lymphadenopathy, upper tract respiratory infection or recent
             contact with someone with conjunctivitis

        Exclusion Criteria:

          -  pregnant women

          -  allergies to non-steroidal anti-inflammatories

          -  history of seasonal allergic conjunctivitis

          -  contact lens wearers

          -  history of ocular herpes infection

          -  blepharitis

          -  severe dry eye

          -  purulent discharge

          -  defects in the corneal epithelium
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Falcão, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundação Altino Ventura</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucio Maranhão, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fundação Altino Ventura</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundação Altino Ventura</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>50070040</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Shiuey Y, Ambati BK, Adamis AP. A randomized, double-masked trial of topical ketorolac versus artificial tears for treatment of viral conjunctivitis. Ophthalmology. 2000 Aug;107(8):1512-7.</citation>
    <PMID>10919900</PMID>
  </reference>
  <reference>
    <citation>Toker MI, Erdem H, Erdogan H, Arici MK, Topalkara A, Arslan OS, Pahsa A. The effects of topical ketorolac and indomethacin on measles conjunctivitis: randomized controlled trial. Am J Ophthalmol. 2006 May;141(5):902-905. Epub 2006 Mar 9.</citation>
    <PMID>16527227</PMID>
  </reference>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conjunctivitis, Viral</keyword>
  <keyword>Ketorolac</keyword>
  <keyword>Artificial tears</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Viral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Lubricant Eye Drops</mesh_term>
    <mesh_term>Carboxymethylcellulose Sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

